Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03364530 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Study acronym: GEMOXIA-02
StatusRecruiting
PhasePhase 2
Started2018-06-11
View on ClinicalTrials.gov ↗

Amendment history

2025-12-31
Study Status v5
Primary completion dateestimated 2025-06-10→confirmed 2025-10-21
Completion date2026-06-10→2026-10-21
2025-01-02
Study Status v4
Primary completion date2024-06-10→2025-06-10
Completion date2025-06-10→2026-06-10
2024-01-15
Study Status v3
Primary completion date2023-06→2024-06-10
Completion date2024-01→2025-06-10
2023-05-02
Study Status v2
Primary completion date2022-06→2023-06
Completion date2023-01→2024-01
2020-01-07
Not Yet Recruiting→Recruiting Study Identification, Study Status, Arms and Interventions, Eligibility, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2022-01→2022-06
Start dateestimated 2018-01→confirmed 2018-06-11
Study sites1→7
Study arms0→1
Eligibility criteria+26 characters
[...] matosis (as demonstrated by CT-scan) General health status : World Health Organization Performance Status = 0, 1 Estimated life expectancy > 3 mon [...]
2017-11-30
Original filing
We hypothesized that intra-arterial gemcitabine/oxaliplatin administered as second-line treatment could strongly improve objective response rate at 4 months after inclusion in patient with non-metastatic unresectable intra-hepatic cholangiocarcinoma.
Trial Details
NCT Number NCT03364530
Lead Sponsor University Hospital, Montpellier
Collaborators: Federation Francophone de Cancerologie Digestive
Conditions Cholangiocarcinoma Non-resectable, Non-metastatic
Enrollment 40 participants
Start Date 2018-06-11
Primary Completion 2025-10-21 (estimated)
Study Completion 2026-10-21 (estimated)
Updated on ClinicalTrials.gov 2026-01-05